SAFETY DATA SHEET  
according to Regulation (EC) No. 1907/2006

Fidaxomicin Solid Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Fidaxomicin Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   Shotton Lane
   NE23 3JU Cramlington - Great Britain
   Telephone : 44 1 670 59 30 00
   Telefax : 908-735-1496
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Acute toxicity, Category 4
   H302: Harmful if swallowed.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms :
   Signal word : Warning
   Hazard statements : H302 Harmful if swallowed.
   Precautionary statements : Prevention:
   P264 Wash skin thoroughly after handling.
   P270 Do not eat, drink or smoke when using this product.
   Response:
   P301 + P312 + P330 IF SWALLOWED: Call a POISON
Hazardous components which must be listed on the label:
Fidaxomicin

2.3 Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fidaxomicin</td>
<td>873857-62-6</td>
<td>Acute Tox. 4; H302</td>
<td>&gt;= 50 - &lt; 70</td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td>532-32-1 208-534-8</td>
<td>Eye Irrit. 2; H319</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
<tr>
<td>Citric acid</td>
<td>77-92-9  201-069-1</td>
<td>Eye Irrit. 2; H319</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.
Get medical attention.
Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed
Risks: Harmful if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed
Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting:
- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Metal oxides
- Chlorine compounds

5.3 Advice for firefighters
Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions: Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions
Environmental precautions:
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling
Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working area.
When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fidaxomicin</td>
<td>873857-62-6</td>
<td>TWA</td>
<td>200 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA (inhalable dust)</td>
<td>10 mg/m³</td>
<td>GB EH40</td>
</tr>
</tbody>
</table>

Further information

For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols, The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m⁻³ 8-hour TWA of inhalable dust or 4 mg.m⁻³ 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with.

| TWA (Respirable dust) | 4 mg/m³ | GB EH40 |
### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium benzoate</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>3 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>0.1 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term local effects</td>
<td>62.5 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>1.5 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>0.06 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>31.25 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>16.6 mg/kg bw/day</td>
</tr>
</tbody>
</table>

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citric acid</td>
<td>Fresh water</td>
<td>0.44 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.044 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>1000 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>34.6 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>3.46 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>33.1 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>Sodium citrate</td>
<td>Fresh water</td>
<td>0.44 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.044 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>1000 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>34.6 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>3.46 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>31.1 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td>Fresh water</td>
<td>0.13 mg/l</td>
</tr>
<tr>
<td></td>
<td>Freshwater - intermittent</td>
<td>0.305 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.013 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>10 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>1.76 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>0.176 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>0.276 mg/kg dry</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Fidaxomicin Solid Formulation

Version 1.0 Revision Date: 08/15/2019 SDS Number: 4757496-00001 Date of last issue: -

| weight (d.w.) | Oral (Secondary Poisoning) 300 mg/kg food |

8.2 Exposure controls

Engineering measures
Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance
with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye protection: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions,
mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a
potential for direct contact to the face with dusts, mists, or
aerosols.

Hand protection
Material: Chemical-resistant gloves

Skin and body protection: Work uniform or laboratory coat.

Respiratory protection: If adequate local exhaust ventilation is not available or expo-
sure assessment demonstrates exposures outside the rec-
ommended guidelines, use respiratory protection.
Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance: granules
Colour: White to light yellow
Odour: No data available
Odour Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: Not applicable
Flammability (solid, gas): May form explosive dust-air mixture during processing, han-
dling or other means.

Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: Not applicable
Fidaxomicin Solid Formulation

Relative vapour density : Not applicable
Relative density : No data available
Density : No data available
Solubility(ies)
- Water solubility : No data available
- Partition coefficient: n-octanol/water : Not applicable
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
- Viscosity, kinematic : Not applicable
 Explosive properties : Not explosive
 Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information
Flammability (liquids) : No data available
Molecular weight : No data available
Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.
SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Harmful if swallowed.

Product:
Acute oral toxicity: Acute toxicity estimate: 875.04 mg/kg
Method: Calculation method

Components:
Fidaxomicin:
Acute oral toxicity: LD50 (Rat): > 1,000 mg/kg
LD50 (Dog): > 120 mg/kg

Acute toxicity (other routes of administration):
LD50 (Rat): 200 mg/kg
Application Route: Intravenous

Sodium benzoate:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
Assessment: The substance or mixture has no acute oral toxicity

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Citric acid:
Acute oral toxicity: LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation
Not classified based on available information.

Components:
Sodium benzoate:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation
Citric acid:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Sodium benzoate:
Species: Rabbit
Method: OECD Test Guideline 405
Result: Irritation to eyes, reversing within 21 days

Citric acid:
Species: Rabbit
Method: OECD Test Guideline 405
Result: Irritation to eyes, reversing within 21 days

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Sodium benzoate:
Test Type: Local lymph node assay (LLNA)
Exposure routes: Skin contact
Species: Mouse
Result: negative
Remarks: Based on data from similar materials

Germ cell mutagenicity
Not classified based on available information.

Components:

Fidaxomicin:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: positive

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Rat
Fidaxomicin Solid Formulation

Application Route: Intravenous  
Result: negative  

Test Type: comet assay  
Species: Rat  
Result: negative  

**Sodium benzoate:**  
Genotoxicity in vitro:  
Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  

Test Type: Chromosome aberration test in vitro  
Result: positive  

Genotoxicity in vivo:  
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative  

**Citric acid:**  
Genotoxicity in vitro:  
Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  

Test Type: in vitro micronucleus test  
Result: positive  

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  

Genotoxicity in vivo:  
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative  

**Carcinogenicity**  
Not classified based on available information.  

**Components:**  
**Sodium benzoate:**  
Species: Rat  
Application Route: Ingestion  
Exposure time: 24 month(s)  
Result: negative  

**Reproductive toxicity**  
Not classified based on available information.
Fidaxomicin Solid Formulation

Components:

Fidaxomicin:
Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Intravenous injection
Fertility: NOAEL: 6.3 mg/kg body weight

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 12.6 mg/kg body weight
Remarks: No significant adverse effects were reported

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 7 mg/kg body weight
Remarks: No significant adverse effects were reported

Sodium benzoate:
Effects on fertility : Test Type: Four-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

Citric acid:
Effects on foetal development : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Fidaxomicin:
Species : Rat
NOAEL : 90 mg/kg
Application Route : Oral
Exposure time : 28 D
## Fidaxomicin Solid Formulation

<table>
<thead>
<tr>
<th>Remarks</th>
<th>: No significant adverse effects were reported</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Species</strong></td>
<td>Rat</td>
</tr>
<tr>
<td><strong>NOAEL</strong></td>
<td>62.5 mg/kg</td>
</tr>
<tr>
<td><strong>Application Route</strong></td>
<td>Intravenous</td>
</tr>
<tr>
<td><strong>Exposure time</strong></td>
<td>14 D</td>
</tr>
<tr>
<td><strong>Species</strong></td>
<td>Dog</td>
</tr>
<tr>
<td><strong>NOAEL</strong></td>
<td>9,600 mg/kg</td>
</tr>
<tr>
<td><strong>Application Route</strong></td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Exposure time</strong></td>
<td>3 M</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td>Vomiting</td>
</tr>
<tr>
<td><strong>Remarks</strong></td>
<td>: No significant adverse effects were reported</td>
</tr>
<tr>
<td><strong>Species</strong></td>
<td>Monkey</td>
</tr>
<tr>
<td><strong>NOAEL</strong></td>
<td>90 mg/kg</td>
</tr>
<tr>
<td><strong>Application Route</strong></td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Exposure time</strong></td>
<td>28 D</td>
</tr>
<tr>
<td><strong>Remarks</strong></td>
<td>: No significant adverse effects were reported</td>
</tr>
<tr>
<td><strong>Species</strong></td>
<td>Juvenile rat</td>
</tr>
<tr>
<td><strong>NOAEL</strong></td>
<td>200 mg/kg</td>
</tr>
<tr>
<td><strong>Application Route</strong></td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Exposure time</strong></td>
<td>28 D</td>
</tr>
<tr>
<td><strong>Remarks</strong></td>
<td>: No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

### Sodium benzoate:

- **Species**: Rat
- **NOAEL**: 1,000 mg/kg
- **Application Route**: Ingestion
- **Exposure time**: 24 Months

### Citric acid:

- **Species**: Rat
- **NOAEL**: 4,000 mg/kg
- **LOAEL**: 8,000 mg/kg
- **Application Route**: Ingestion
- **Exposure time**: 10 Days

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

**Fidaxomicin:**

- **Ingestion**: Symptoms: Abdominal pain, Nausea, Vomiting, constipation
### SECTION 12: Ecological information

#### 12.1 Toxicity

**Components:**

**Fidaxomicin:**

| Toxicity to algae/aquatic plants | EC50 (Anabaena flos-aquae (cyanobacterium)): > 18.4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
| Remarks: No toxicity at the limit of solubility |
| NOEC (Anabaena flos-aquae (cyanobacterium)): 5.8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| Remarks: No toxicity at the limit of solubility |

| Toxicity to microorganisms | EC50: > 50 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 |
| NOEC: 5.9 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 |

| Toxicity to fish (Chronic toxicity) | NOEC: 8.91 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility |

| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | NOEC: 19.6 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211 |

**Sodium benzoate:**

| Toxicity to fish | LC50 (Pimephales promelas (fathead minnow)): 484 mg/l Exposure time: 96 h |
| Toxicity to daphnia and other aquatic invertebrates | EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 96 h |
| Toxicity to algae/aquatic plants | EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 32 mg/l Exposure time: 72 h |
12.2 Persistence and degradability

**Components:**

**Sodium benzoate:**
Biodegradability: Result: Readily biodegradable.
Biodegradation: 75 %
Exposure time: 28 d

**Citric acid:**
Biodegradability: Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

12.3 Bioaccumulative potential

**Components:**

**Fidaxomicin:**
Partition coefficient: n-octanol/water: log Pow: 4.4

**Sodium benzoate:**
Partition coefficient: n-octanol/water: log Pow: 1.88

**Citric acid:**
Partition coefficient: n-octanol/water: log Pow: -1.72

12.4 Mobility in soil

**Components:**

**Fidaxomicin:**
Distribution among environmental compartments: log Koc: 0.80

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available
SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

14.3 Transport hazard class(es)

Not regulated as a dangerous good

14.4 Packing group

Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable

REACH - List of substances subject to authorisation (Annex XIV): Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable

Regulation (EC) No 850/2004 on persistent organic pollutants: Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
   Not applicable

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H302 : Harmful if swallowed.
H319 : Causes serious eye irritation.

Full text of other abbreviations
Acute Tox. : Acute toxicity
Eye Irrit. : Eye irritation
GB EH40 : UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA : Long-term exposure limit (8-hour TWA reference period)
GB EH40 / STEL : Short-term exposure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Develop-
Fidaxomicin Solid Formulation

Further information

Classification of the mixture: Acute Tox. 4 H302
Calculation procedure: Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.

Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN